The growing rates of obesity are increasing the use of GLP-1 for weight management
This investigation utilizes the FAERS database to conduct a large-scale pharmacoepidemiologic analysis, aiming to generate robust real-world evidence regarding the safety profile of GLP-1 receptor agonist and metformin combination therapy through systematic evaluation of reported adverse events
Expanding GLP-1 Indications Beyond Obesity and Diabetes While obesity and type 2 diabetes remain the primary targets for GLP-1 drugs, there is growing interest in expanding the use of these drugs to treat other metabolic and cardiovascular conditions
Every clinical trial shows not just if a drug works, but how the body talks back
JUSTBEAUTY Germany Laboratory unveils the 2nd generation of its Liposomal Glutathione: an even more effective, bioavailable and powerful formula
12, 17, 18 These studies are presently taken very seriously and weighted with regard to the benefits of incretin therapy in diabetes